| SC 13D/A | 2024-02-22 | Arkin Moshe | UroGen Pharma Ltd. | - | 4.4% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | UroGen Pharma Ltd. | 3,083,558 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | GREAT POINT PARTNERS LLC | UroGen Pharma Ltd. | 2,620,545 | 8.5% | EDGAR |
| SC 13G/A | 2024-02-14 | MENORA MIVTACHIM HOLDINGS LTD. | UroGen Pharma Ltd. | 2,303,031 | 7.5% | EDGAR |
| SC 13G | 2024-02-14 | RTW INVESTMENTS, LP | UroGen Pharma Ltd. | 1,726,808 | 5.6% | EDGAR |
| SC 13G/A | 2024-02-13 | Stonepine Capital Management, LLC | UroGen Pharma Ltd. | 0 | 0.0% | EDGAR |
| SC 13G | 2024-02-02 | BlackRock Inc. | UroGen Pharma Ltd. | 1,719,304 | 5.6% | EDGAR |
| SC 13G | 2023-12-29 | RA CAPITAL MANAGEMENT, L.P. | UroGen Pharma Ltd. | 3,083,550 | 10.0% | EDGAR |
| SC 13G | 2023-09-15 | GREAT POINT PARTNERS LLC | UroGen Pharma Ltd. | 2,620,545 | 8.5% | EDGAR |
| SC 13D | 2023-08-04 | Monograph Capital Holdings Advisors, LLC | UroGen Pharma Ltd. | 1,572,327 | 5.1% | EDGAR |
| SC 13G/A | 2023-06-12 | MENORA MIVTACHIM HOLDINGS LTD. | UroGen Pharma Ltd. | 291,900,290 | 12.4% | EDGAR |
| SC 13G/A | 2023-02-13 | Stonepine Capital Management, LLC | UroGen Pharma Ltd. | 1,304,947 | 5.7% | EDGAR |
| SC 13G | 2022-12-01 | Stonepine Capital Management, LLC | UroGen Pharma Ltd. | 1,196,908 | 5.2% | EDGAR |
| SC 13G | 2022-07-08 | BlackRock Inc. | UroGen Pharma Ltd. | 340,412 | 1.5% | EDGAR |
| SC 13G/A | 2022-02-14 | Wildcat Capital Management, LLC | UroGen Pharma Ltd. | 533,139 | 2.4% | EDGAR |
| SC 13G/A | 2022-02-14 | CREDIT SUISSE AG/ | UroGen Pharma Ltd. | 1,085,749 | 4.8% | EDGAR |
| SC 13G/A | 2022-02-04 | WELLINGTON MANAGEMENT GROUP LLP | UroGen Pharma Ltd. | 238,008 | 1.1% | EDGAR |
| SC 13G/A | 2022-02-03 | BlackRock Inc. | UroGen Pharma Ltd. | 1,728,094 | 7.7% | EDGAR |
| SC 13G/A | 2021-02-12 | Wildcat Capital Management, LLC | UroGen Pharma Ltd. | 533,139 | 2.4% | EDGAR |
| SC 13G | 2021-02-12 | CREDIT SUISSE AG/ | UroGen Pharma Ltd. | 1,121,071 | 507.0% | EDGAR |